Thank you, Sohanya.
footprint in future and in We we to to of territories ex-U.S. one myeloma look have is our as the multiple our strategically XX, selinexor priorities key partnered Slide the across expand top globe. on
As therapy. following with Europe Phase with least from our touched opinion on recently and the in Menarini Richard, upon May, approval multiple partners just bortezomib Karyopharm BOSTON The at the based in in one and myeloma, prior combination obtained by CHMP by NEXPOVIO patients study. in follows granted results XXXX, III approval a positive for dexamethasone
In addition, Hong and Canada selinexor Mainland partners. in strategic Kong China, in launched was our recently through
which will now XX, to I reviewing focus pipeline, of consistent years. potential has the a to four two deliver Slide our to over the be steady stream new approvals next Turning in and developmental
need outcomes. combinations to patients myeloma of ability with turn the significantly XX, patient first unmet modalities you physician’s The to refractory strong As given in like from Unfortunately, myeloma patients' remains and selinexor switch has Slide due multiple resistance, better treated because many based new multiple relapsed incurable to driven second is for IMiD disease class the majority to relapse or treatment multiple of treat still treatment. considered disease an are therefore to an these an drug anti-CDXX, become and PI acquired line regimen. will anti-CDXX inevitable to
for the believe only physicians data to increasingly has regimens, the the post and and the promote which with of this different is in an several option setting approved while We strongest clinical support the the Our NCCN in manageable fit. FDA we Selinexor understood combine selinexor backbones selinexor setting. guidelines. has use have profile, anti-CDXX safety
which emergence the therapies, including fitness, underscore considering stem data treatment. evolving a and are engaging new with immunotherapies cellular the optimal investigating needed and myeloma XPOX inhibition we Additionally, plays for T-cell actively preserving T-cell role in of and multiple believe landscape treatments, for We is XPOXinhibition therapies, will cell an this of and collection Selinexor as role earlier anchor patients these further therapies environment. immune in robust line maintaining the cellular
achieving care XX, If myelofibrosis would I patients JAK the for you the slide approved our treatment. other to years. frontline than have myelofibrosis XX% fibrosis drug XX inhibitors diagnosed treatment newly of now landscape. the in standard spleen only rapidly other of a with of XX% a would to approximately like turn current last been as volume reduction program advancing Ruxolitinib highlight is classes, of current No and
a on myelofibrosis evaluating and of outlined frontline study ruxolitinib Our treatment naive study selinexor combination with this patients the in Phase slide is myelofibrosis. I/II
to ruxolitinib of and this the evaluate efficacy on and population, activity patient line this both myelofibrosis in of Our first goals study compounds. are agent for selinexor single safety the building
drugs, potential that combination these the two the or multiple we parameters, potential upon selinexor plus synergism between improving to believe Given of ruxolitinib including improve the burden. symptom has efficacy maintaining
no Association XX. equal dose study, recently X patients began had greater far encouraging XX% presented These ASCO at shown has spleen at Congress. which with follow favorable European treatment maintained The toxicities volume and mid-XXXX of XX. I Slide week XXXX weeks data results to in included of at improved to valuable XX% Phase limiting hemoglobin thus or results levels or the transfusion XXXX of with Hematology Turning XX% up. tolerability a independent reduction least stable hemoglobin patients at The and demonstrating last preliminary who
In been treatment to reduction X had XX on having greater symptom who the rapid reductions evaluable in XX% complete weeks data at seven experienced equal their week or least had patients at with patients and XX. addition, all scores X of a of for
and dose can Turning selinexor level Phase and and X toxicities anemia expected of this grade The generally enrolled adverse to you Currently, portion patients study, being both dose study. Xb you to the tolerated the either Phase of reversible ruxolitinib the with events that ruxolitinib slide with to slide in combination in reported dose with XX, the portion can are adverse study evaluable events were manageable, of XX, and were of reported be scores most On at all with TSSXX selinexor reductions dosed interruptions occurred patient hematologic the and thrombocytopenia, common detailed SVRXX being of selinexor. see well that no the patients XA in was the and see X the last limiting month. neutropenia.
present expect study of from the to in second updated We half XXXX. clinical the data
novel continue we in top XXX development look of in action. previously our treated and myelofibrosis with we to in our enroll half we myelofibrosis results study, forward the to XXXX, line as program deliver of Additionally, second robust report this mechanism a
find unmet like to need would turn cancer and we so upcoming as opportunity I Now, slide our XX, for in endometrial to discuss exciting we why the patients.
tumors common is States First, XX% the endometrial United cancer the in most wild-type. of form of gynecologic approximately cancer as pXX classified with
one used offer the XXXX, at and of molecular oncology exploratory clinical risk improve a sustain the response from of the SIENDO believe study wait cancer. that classification for treatment cancer, has Next, the to maintenance consists analysis Atlas, selinexor and that line patient and chemotherapy. completion molecular population year Cancer until first including This treat approach recurrent physicians evaluating gynecologic endometrial well maintenance subgroup Selinexor distinct in watch patients. needs this survival algorithms therapy is benefit Genome the overall SIENDO rate in current multiple administered to analysis that We guidelines in cancer breast given assessed of established and ovarian with the for could tumors, preliminary potential of recommend for from solid chemotherapy four prognostic orally chemotherapy, subgroups XX%. data only Presented the and is progression. types NCCN these of is using subtypes the a the the Upon ASCO clearly scores. advanced accepted or study, approach improvement, a disease of landscape that selinexor endometrial is five the endometrial calculate option cancer
robust were patients progression treated survival X.X for with demonstrated with analysis months treated pXX wild-types were months of months free whose disclosed, As compared with patients XX.X demonstrated survival median selinexor selinexor tumors to months previously indicated selinexor of compared this endometrial the X.X we and that are and provide partner median advance and them. whose the agreement we productive to dialogue treated a with patients wild-type or be pXX diagnostic has pXX upon suggests patients selected In the either contrast, have placebo. companion a biomarker process with progression a finalizing with meaningful FDA, cancer. potential patients X.X tumors may mutant that placebo. have free to Based in data treated for with wild-type These had an to pXX benefits
remain this of advance XX close the to Mike second ENGOT now the the to ongoing the We and review and are initiate to over the and that, quarter call Mike? quarter fourth both track GOG Phase financial trial Slide I'll year. with registration excited with X to enabling With on turn in collaboration highlights.
